Capital Fund Management (CFM)’s Axsome Therapeutics AXSM Stock Holding History

Capital Fund Management (CFM)’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-28,758	Closed	-$3.49M	–	2359
2025 Q3	$3.49M	Sell	28,758 -32,005	-53%	-$3.61M	0.01%	1465
2025 Q2	$6.34M	Buy	60,763 +47,738	+367%	+$5.05M	0.02%	997
2025 Q1	$1.52M	Buy	+13,025	New	+$1.48M	﹤0.01%	1526
2023 Q1	–	Sell	-19,283	Closed	-$1.49M	–	1551
2022 Q4	$1.49M	Buy	+19,283	New	+$1.15M	0.01%	1027
2022 Q3	–	Sell	-13,133	Closed	-$503K	–	1408
2022 Q2	$503K	Sell	13,133 -19,045	-59%	-$602K	﹤0.01%	1247
2022 Q1	$1.33M	Buy	+32,178	New	+$997K	0.01%	1079

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s AXSM Position: Q4 2025 in Review

Capital Fund Management (CFM) sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 28,758 shares — an estimated $3.49M sold.

Capital Fund Management (CFM) first reported a position in AXSM in Q1 2022 and held it in 6 quarters. The position peaked at $6.34M in Q2 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

Capital Fund Management (CFM) reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 28,758 Axsome Therapeutics shares in Q4 2025, an estimated $3.49M.
Capital Fund Management (CFM) first reported a position in Axsome Therapeutics in Q1 2022 and held it in 6 quarters.
Capital Fund Management (CFM)'s Axsome Therapeutics position peaked at $6.34M in Q2 2025.
398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2025, filed 17 Feb 2026.